The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.
Pharmacy Intelligence applies application-based data analytics, computer-animated graphic process simulation and Lean Six Sigma principles to enable a new level of more advanced modeling and forecasting.
Towers Watson on Tuesday announced that it has selected Loblaw Companies as the preferred pharmacy services provider for its Towers Watson Canadian Rx Coalition, a collaborative network of private sector drug plan sponsors.
Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion.